CPHI China 2026 in Shanghai has officially come to a close, and what an incredible event it was for the global pharmaceutical community. CPHI China 2026 in Shanghai: A Successful Event for JYMed Peptide Over three dynamic days, thousands of pharma professionals,...
May 29 | 1. CSPC enters a $18.5 billion global licensing deal with AstraZeneca for peptide platform (including GLP-1 pipeline) Key Highlights: The deal comprises an upfront payment of $1.2 billion and a total potential value of up to $18.5 billion, setting a new...
We are pleased to announce that Dr. Beatriz G. de la Torre has joined JYMed Peptide as Principal Scientific Advisor.Dr. de la Torre has spent over three decades working at the intersection of peptide chemistry and biomedical research, with academic and research...
We are pleased to announce that Professor Fernando Albericio has joined JYMed Peptide as Chief Scientific Advisor.It is a privilege to welcome him to the team. Internationally recognized for his extensive contributions to peptide chemistry, including solid-phase...
Behind every peptide project, there are people making the work possible.From research and production to quality, operations, and customer support, Labor Day is the perfect time to recognize the teams whose dedication makes everything possible, every day.Happy Labor...
JYMed Peptide’s New Semaglutide DMF No. 041090 Listed as “Available for Reference” by the U.S. FDA JYMed Peptide recently announced that an additional Drug Master File (DMF) for its Semaglutide active pharmaceutical ingredient (API), DMF No. 041090, has successfully...
Recently, Hubei JXBio Pharmaceutical Co., Ltd. ("Hubei JXBio"), the peptide manufacturing base of Jianyuan Pharmaceuticals, received the Chemical API Marketing Approval Notification for Icatibant Acetate (Registration No.: Y20240000910) issued by the...
To Our Valued Clients, Partners, and Friends, We are pleased to announce the appointment of Dr. ZhaoBo Gao as Chief Operating Officer (COO) of JYMed Peptide. Dr. Gao brings more than 20 years of successful experience in...
Date: March 2026 | 1. FDA Crackdown on Unapproved Compounded GLP-1 Products The U.S. FDA issued 30 warning letters to telehealth companies and compounding pharmacies marketing unapproved compounded GLP-1 products (e.g., semaglutide, tirzepatide) with false efficacy...
中文